I love that PYC presentations frequently include relevant and up-to-date industry insights.
Slide 6 is the star slide today – from a Stifel presentation this month, a graph shows average enterprise values of US-listed biopharma compared by development stage and quality of data.
Look at that stacked back left “winner takes all” corner!
It shows that the average EV for a Phase 3 biopharma with a top quality dataset is now close to US$4bn (A$5.8bn), dwarfing, for example, the US$137m average EV of a Phase 3 company with medium quality data or the $269m average EV of a Phase 3 company with mere“good” data.
Says Stifel “We have not seen a quality premium like this before in biotech”.
This graph truly drives home the importance of quality data.
And I’m expecting that PYC will deliver just that…
PYC Price at posting:
17.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)